Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC).

Passiglia F, Priedane E, Mardiguian S, Farraia M, Pandey A, Shukla P, Wilamowitz-Moellendorff CV, Rivolo S, Mendoza-Naranjo A, Leaw S, Naicker K, Wang Y, Lin X, Kapetanakis V

Open source

DOI: 10.1080/14796694.2026.2696934
Published: 2026 Aug
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2696934,
  title = {Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC).},
  author = {Passiglia F and Priedane E and Mardiguian S and Farraia M and Pandey A and Shukla P and Wilamowitz-Moellendorff CV and Rivolo S and Mendoza-Naranjo A and Leaw S and Naicker K and Wang Y and Lin X and Kapetanakis V},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2696934},
  url = {https://doi.org/10.1080/14796694.2026.2696934}
}

RIS

TY  - JOUR
TI  - Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC).
AU  - Passiglia F
AU  - Priedane E
AU  - Mardiguian S
AU  - Farraia M
AU  - Pandey A
AU  - Shukla P
AU  - Wilamowitz-Moellendorff CV
AU  - Rivolo S
AU  - Mendoza-Naranjo A
AU  - Leaw S
AU  - Naicker K
AU  - Wang Y
AU  - Lin X
AU  - Kapetanakis V
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2696934
UR  - https://doi.org/10.1080/14796694.2026.2696934
ER  -

APA

F, P., E, P., S, M., M, F., A, P., P, S., CV, W., S, R., A, M., S, L., K, N., Y, W., X, L., & V, K. (2026). Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC).. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2696934

Source records

pubmed · retrieved 2026-09-27T01:27:27.080Z